Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer

Table 5 Comparison of life quality

Indicators	Time	Observation group, n = 46	Control group, n = 46	t	P value
Functional domains	Before treatment	35.12 ± 4.06	35.40 ± 4.57	0.311	0.757
	After treatment	42.10 ± 6.061	39.11 ± 5.741	2.430	0.017
Symptom domains	Before treatment	17.52 ± 3.24	17.06 ± 3.00	0.707	0.482
	After treatment	10.42 ± 1.571	14.20 ± 2.171	9.572	0.000
General health status/quality of life domains	Before treatment	7.52 ± 0.85	7.23 ± 0.89	1.598	0.114
	After treatment	11.54 ± 1.471	9.24 ± 1.031	8.691	0.000
Individual item measurements	Before treatment	17.41 ± 2.09	17.26 ± 2.47	0.314	0.754
	After treatment	13.02 ± 1.221	15.05 ± 1.541	7.008	0.000

¹Denotes a comparison with the pre-treatment values. Data are mean scores ± SD.